182 related articles for article (PubMed ID: 27270908)
1. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
Mandel JJ; Cachia D; Liu D; Wilson C; Aldape K; Fuller G; de Groot JF
J Neurooncol; 2016 Aug; 129(1):147-54. PubMed ID: 27270908
[TBL] [Abstract][Full Text] [Related]
2. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
3. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
4. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
5. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
6. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
8. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Khan I; Waqas M; Shamim MS
J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
[TBL] [Abstract][Full Text] [Related]
10. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
12. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas.
Argadal OG; Mutlu M; Ak Aksoy S; Kocaeli H; Tunca B; Civan MN; Egeli U; Cecener G; Bekar A; Taskapilioglu MO; Tekin C; Tezcan G; Tolunay S
Bosn J Basic Med Sci; 2020 Feb; 20(1):63-69. PubMed ID: 31479414
[TBL] [Abstract][Full Text] [Related]
14. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
[TBL] [Abstract][Full Text] [Related]
17. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
19. A clinical evaluation of cystic features in patients with newly diagnosed glioblastoma with IDH-wildtype.
Kim MJ; Park JS; Jeun SS; Ahn S
Clin Neurol Neurosurg; 2023 May; 228():107708. PubMed ID: 37043844
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
